TY - JOUR
T1 - The impact of partial-oral endocarditis treatment on anxiety and depression in the POET trial
AU - Bundgaard, Johan S
AU - Iversen, Kasper
AU - Pries-Heje, Mia
AU - Ihlemann, Nikolaj
AU - Bak, Theis S
AU - Østergaard, Lauge
AU - Gill, Sabine U
AU - Madsen, Trine
AU - Elming, Hanne
AU - Jensen, Kaare T
AU - Bruun, Niels E
AU - Høfsten, Dan E
AU - Fuursted, Kurt
AU - Christensen, Jens J
AU - Schultz, Martin
AU - Rosenvinge, Flemming
AU - Schønheyder, Henrik C
AU - Helweg-Larsen, Jannik
AU - Køber, Lars
AU - Torp-Pedersen, Christian
AU - Fosbøl, Emil L
AU - Tønder, Niels
AU - Moser, Claus
AU - Bundgaard, Henning
AU - Mogensen, Ulrik M
N1 - Copyright © 2022 Elsevier Inc. All rights reserved.
PY - 2022/3
Y1 - 2022/3
N2 - BACKGROUND: The Partial-Oral versus Intravenous Antibiotic Treatment of Endocarditis Trial (POET) found that partial-oral outpatient treatment was non-inferior to conventional in-hospital intravenous treatment in patients with left-sided infective endocarditis. We examined the impact of treatment strategy on levels of anxiety and depression.METHODS: Patients completed the Hospital Anxiety and Depression Scale (HADS) at randomization, at antibiotic completion, and after month 3 and month 6. Changes in anxiety and depression (each subdimension 0-21, high scores indicating worse) were calculated using a repeated measure analysis of covariance model with primary assessment after 6 months. Change in score of 1.7 represented a minimal clinical important difference (MCID).RESULTS: Among the 400 patients enrolled in the POET trial, 263 (66%) completed HADS at randomization with reassessment rates of 86-87% at the three subsequent timepoints. Patients in the partial-oral group and the intravenous group had similar improvements after 6 months in levels of anxiety (-1.8 versus -1.6, P = 0.62) and depression (-2.1 versus -1.9, P = 0.63), although patients in the partial-oral group had numerically lower levels of anxiety and depression throughout. An improvement in MCID scores after 6 months was reported by 47% versus 45% (p = 0.80) patients for anxiety and by 51% versus 54% (p = 0.70) for depression.CONCLUSION: Patients with endocarditis receiving partial-oral outpatient treatment reported similar significant improvements in anxiety and depression at 6 months, as compared to conventionally treated, but numerically lower levels throughout. These findings support the usefulness of partial-oral treatment.
AB - BACKGROUND: The Partial-Oral versus Intravenous Antibiotic Treatment of Endocarditis Trial (POET) found that partial-oral outpatient treatment was non-inferior to conventional in-hospital intravenous treatment in patients with left-sided infective endocarditis. We examined the impact of treatment strategy on levels of anxiety and depression.METHODS: Patients completed the Hospital Anxiety and Depression Scale (HADS) at randomization, at antibiotic completion, and after month 3 and month 6. Changes in anxiety and depression (each subdimension 0-21, high scores indicating worse) were calculated using a repeated measure analysis of covariance model with primary assessment after 6 months. Change in score of 1.7 represented a minimal clinical important difference (MCID).RESULTS: Among the 400 patients enrolled in the POET trial, 263 (66%) completed HADS at randomization with reassessment rates of 86-87% at the three subsequent timepoints. Patients in the partial-oral group and the intravenous group had similar improvements after 6 months in levels of anxiety (-1.8 versus -1.6, P = 0.62) and depression (-2.1 versus -1.9, P = 0.63), although patients in the partial-oral group had numerically lower levels of anxiety and depression throughout. An improvement in MCID scores after 6 months was reported by 47% versus 45% (p = 0.80) patients for anxiety and by 51% versus 54% (p = 0.70) for depression.CONCLUSION: Patients with endocarditis receiving partial-oral outpatient treatment reported similar significant improvements in anxiety and depression at 6 months, as compared to conventionally treated, but numerically lower levels throughout. These findings support the usefulness of partial-oral treatment.
UR - http://www.scopus.com/inward/record.url?scp=85123194068&partnerID=8YFLogxK
U2 - 10.1016/j.jpsychores.2022.110718
DO - 10.1016/j.jpsychores.2022.110718
M3 - Journal article
C2 - 35078079
SN - 0022-3999
VL - 154
SP - 110718
JO - Journal of Psychosomatic Research
JF - Journal of Psychosomatic Research
M1 - 110718
ER -